Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study

Published:2020-04-06 Issue:5 Volume:14 Page:754-764
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Chen Zhen-Hua,Zhang Xiu-Ping,Lu Yu-Gang,Li Le-Qun,Chen Min-Shan,Wen Tian-Fu,Jia Wei-Dong,Zhou Dong,Li Jing,Yang Ding-Hua,Zhen Zuo-Jun,Xia Yi-Jun,Fan Rui-Fang,Huang Yang-Qing,Zhang Yu,Wu Xiao-Jing,Hu Yi-Ren,Tang Yu-Fu,Lin Jian-Hua,Zhang Fan,Zhong Cheng-Qian,Guo Wei-Xing,Shi Jie,Lau Joseph,Cheng Shu-Qun^ORCID

Funder

Key Project of Natural Science Foundation of China

National Key Basic Research Programme “973 project”

National Natural Science Foundation of China

Shanghai Municipal Health Bureau

Shanghai Science and Technology Committee

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-020-10032-2.pdf

Reference30 articles.

1. European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

2. Bruix J, Sherman M. American Association for the study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

3. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48(1):103–9.

4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review;Frontiers in Oncology;2024-05-24

2. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience;Translational Cancer Research;2024-05

3. Long-term surgical outcomes of bile duct tumor thrombus versus portal vein tumor thrombus for hepatocellular carcinoma: a propensity score matching analysis;Frontiers in Oncology;2024-04-02

4. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis;Frontiers in Oncology;2024-02-16

5. 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations;Journal of Clinical and Experimental Hepatology;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3